Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.
The Food and Drug Administration (FDA) recently approved a supplemental New Drug Application (sNDA) for Pentasa (melamine), updating the therapy’s path of ... Read more
Children suffering from inflammatory bowel disease (IBD) who are reacting positively to prescribed biological medications should not have their prescriptions changed to recently approved “biosimilar” ... Read more
TxCell SA is a biotechnology firm advancing innovative and personalized T cell immunotherapies utilizing antigen specific regulatory T-cells (Ag-Tregs) to address both severe chronic inflammatory ... Read more
The National Board of Trustees recently announced that Michael Osso was selected to become the next President & CEO of the Crohn’s & Colitis Foundation ... Read more
Founded by the renowned philanthropist and economist Sanford J. Grossman, The Sanford J. Grossman Charitable Trust was recently awarded $3 million to ... Read more
In an effort to raise support for families and patients suffering from inflammatory bowel diseases, the Crohn’s & Colitis Foundation of America (CCFA) recently announced three companies ... Read more
Qu Biologics Inc., a biotechnology firm currently developing Site Specific Immunomodulators (SSIs) to restore regular immune function in a specific targeted diseased organ, recently announced ... Read more
A key patent was recently granted by the United States Patent and Trademark Office (USPTO) to TxCell SA for its lead product Ovasave® to address inflammatory bowel disease ... Read more
